Puma launches breast cancer drug Nerlynx in U.S.

Puma Biotechnology Inc. (NASDAQ:PBYI) launched Nerlynx oral neratinib in the U.S. as extended adjuvant treatment for patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant Herceptin trastuzumab-based therapy. The wholesale acquisition cost (WAC) for a 40 gram pill is $58.33. The recommended dose is 240 mg once daily for a year...